Skip To Main Content
This platform is for Australian healthcare professionals only
Campus
Campus

EVENT TWO

2023 Interactive Clinical Tutorial Series

Remission or 'super responders' in severe asthma:

same or different?

Recorded on: 10 August 2023

At this special ADVENT meeting, our expert multi-disciplinary panel embarked on a journey to unlock the meaning behind two concepts in the management of patients with severe asthma: remission or super responders.

By unravelling the insights and experiences of esteemed colleagues from the fields of respiratory medicine, respiratory oncology, immunology and rheumatology, our experts uncovered valuable parallels applicable to severe asthma and debated the differences between remission and super responder.

Prepare to have your perspective challenged, your curiosity ignited, and your passion for better patient care satisfied by the seven videos below.

Asthma definitions of remission

Prof Peter Wark discusses the concept and definitions of remission and super responder within asthma

Remisssion in Lung Oncology

A/Prof Stone discusses the concept of remission in lung oncology

Remission in rheumatology: concept of treat to target

Dr Tellus discusses the treat to target approach to achieve remission in rheumatology

Watch the 2020–2022 ADVENT and ASPIRE series developed and endorsed by Australian and international experts

At ADVENTprogram.com you can:

  • Access medical education resources
  • Review the latest science for type 2 inflammatory diseases
  • Explore your specific interests – select materials by category or topic

Login to ADVENTprogram.com

Access to ADVENTprogram.com is restricted to healthcare professionals. Registration is required to view content.

DUPIXENT (dupilumab) PBS Information: Authority Required.

Refer to PBS schedule for full authority information. Authority required for patients aged ≥12 years with: chronic severe atopic dermatitis: OR uncontrolled severe asthma.  This product is not listed on the PBS for: children 6 months to 11 years of age with severe atopic dermatitis; children 6-11 years of age with moderate to severe asthma; adults with uncontrolled chronic rhinosinusitis with nasal polyps; or adults with moderate-to-severe prurigo nodularis.

Please review the full Product Information before prescribing Dupixent (dupilumab). Please review full product Information before prescribing Dupixent (dupilumab). Full Product Information is available from Sanofi-aventis Australia pty ltd here or by contacting 1800 818 806.

â–¼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems

MAT-AU-2302086 (v1.0)  |  SEPTEMBER 2023